MA25563A1 - Pyridines et pyridazines substitues avec une activite inhibitrice angiogenese. - Google Patents

Pyridines et pyridazines substitues avec une activite inhibitrice angiogenese.

Info

Publication number
MA25563A1
MA25563A1 MA26619A MA26619A MA25563A1 MA 25563 A1 MA25563 A1 MA 25563A1 MA 26619 A MA26619 A MA 26619A MA 26619 A MA26619 A MA 26619A MA 25563 A1 MA25563 A1 MA 25563A1
Authority
MA
Morocco
Prior art keywords
angiogenically
pyridines
inhibiting activity
substituted pyridazines
pyridazines
Prior art date
Application number
MA26619A
Other languages
English (en)
Inventor
Lee Wendy
Nagarathnam Dhanapalan
Su Ning
P Dumas Jacques
A Dixon Julie
Kite Joe Teddy
C E Kluender Harold
N Sibley Robert
J Boyer Stephen
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA25563A1 publication Critical patent/MA25563A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
MA26619A 1999-09-28 2002-04-26 Pyridines et pyridazines substitues avec une activite inhibitrice angiogenese. MA25563A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28

Publications (1)

Publication Number Publication Date
MA25563A1 true MA25563A1 (fr) 2002-10-01

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26619A MA25563A1 (fr) 1999-09-28 2002-04-26 Pyridines et pyridazines substitues avec une activite inhibitrice angiogenese.

Country Status (35)

Country Link
EP (1) EP1228063B1 (fr)
JP (1) JP4919567B2 (fr)
KR (3) KR100890473B1 (fr)
CN (3) CN100374435C (fr)
AR (3) AR025752A1 (fr)
AT (1) ATE422494T1 (fr)
AU (1) AU782820B2 (fr)
BG (1) BG65860B1 (fr)
BR (1) BRPI0014382B8 (fr)
CA (1) CA2385817C (fr)
CO (1) CO5200835A1 (fr)
CZ (1) CZ304767B6 (fr)
DE (1) DE60041548D1 (fr)
DO (1) DOP2000000070A (fr)
EE (1) EE05258B1 (fr)
ES (1) ES2320525T3 (fr)
GT (1) GT200000158A (fr)
HR (1) HRP20020308A2 (fr)
HU (1) HU230223B1 (fr)
IL (3) IL148880A0 (fr)
MA (1) MA25563A1 (fr)
MX (1) MXPA02003156A (fr)
MY (3) MY143580A (fr)
NO (1) NO20021520L (fr)
NZ (1) NZ518589A (fr)
PA (1) PA8503201A1 (fr)
PE (1) PE20010607A1 (fr)
PL (1) PL205957B1 (fr)
RS (1) RS50369B (fr)
RU (1) RU2260008C2 (fr)
SK (1) SK287417B6 (fr)
TW (1) TW593315B (fr)
UA (1) UA75053C2 (fr)
WO (1) WO2001023375A2 (fr)
ZA (1) ZA200202760B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207878A1 (en) * 2000-08-09 2003-11-06 Hennequin Lawrent Francois Andre Chemical compounds
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
CA2471314A1 (fr) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Polytherapies antiangiogeneses a base de derives de pyridazine ou pyridine
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
KR20050108383A (ko) * 2003-03-11 2005-11-16 노파르티스 아게 이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도
EP1616576A4 (fr) * 2003-04-08 2010-02-10 Mitsubishi Tanabe Pharma Corp Inhibiteur d'oxydase nad(p)h specifique
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-c]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
WO2006030941A1 (fr) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. Utilisation concomitante d'un compose contenant du sulfonamide et d'un inhibiteur d'angiogenese
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
CA2648957A1 (fr) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Composes pour traiter une hypertension pulmonaire
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
WO2008093855A1 (fr) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
CA2704000C (fr) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combinaison d'une substance antiangiogenique et d'un complexe de platine antitumoral
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
CA2771403C (fr) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Composition pharmaceutique contenant un derive de quinoleine
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CA2912219C (fr) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarqueurs pour predire et evaluer la reponse de sujets atteints de cancer de l'endometre a des composes a base de lenvatinib
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
EP3187491A4 (fr) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. Dérivé de quinoline de pureté élevée et son procédé de fabrication
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业(泰州)有限公司 一种工业化生产甲磺酸特拉替尼的方法
CA2988707C (fr) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combinaison de proteine se liant au cre/inhibiteur de catenine et d'un inhibiteur de point de controle immunitaire servant au traitement du cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
WO2018212202A1 (fr) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Traitement du carcinome hépatocellulaire
US12421228B2 (en) * 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
US20250129067A1 (en) 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
EP0722936B1 (fr) * 1994-08-09 2004-05-19 Eisai Co., Ltd. Compose de pyridazine condense
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ES2342240T3 (es) * 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
ATE329596T1 (de) * 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
WO2001058899A1 (fr) * 2000-02-09 2001-08-16 Novartis Ag Derives de pyridine inhibant l'angiogenese et/ou la tyrosine-kinase du recepteur de vegf

Also Published As

Publication number Publication date
AR082231A2 (es) 2012-11-21
DOP2000000070A (es) 2002-02-28
IL193367A (en) 2011-03-31
HUP0202704A2 (hu) 2002-12-28
YU22902A (sh) 2004-12-31
IL193368A0 (en) 2009-02-11
HRP20020308A2 (en) 2004-06-30
KR100895571B1 (ko) 2009-04-29
RU2260008C2 (ru) 2005-09-10
CN100422172C (zh) 2008-10-01
NO20021520D0 (no) 2002-03-26
HUP0202704A3 (en) 2003-12-29
CA2385817A1 (fr) 2001-04-05
EP1228063B1 (fr) 2009-02-11
CA2385817C (fr) 2010-05-04
BR0014382B1 (pt) 2014-04-01
HU230223B1 (en) 2015-10-28
CN1420879A (zh) 2003-05-28
IL148880A0 (en) 2002-09-12
PL205957B1 (pl) 2010-06-30
KR20080091505A (ko) 2008-10-13
EE200200161A (et) 2003-08-15
CZ304767B6 (cs) 2014-10-08
ATE422494T1 (de) 2009-02-15
KR100890473B1 (ko) 2009-03-26
GT200000158A (es) 2002-03-16
MY143377A (en) 2011-05-13
BR0014382A (pt) 2003-06-24
CZ20021444A3 (cs) 2002-08-14
MY143580A (en) 2011-05-31
KR20080086547A (ko) 2008-09-25
AR082232A2 (es) 2012-11-21
CN1769282A (zh) 2006-05-10
EP1228063A2 (fr) 2002-08-07
CN1769283A (zh) 2006-05-10
SK287417B6 (sk) 2010-09-07
NZ518589A (en) 2005-03-24
MY135058A (en) 2008-01-31
KR20020038775A (ko) 2002-05-23
JP4919567B2 (ja) 2012-04-18
HK1091819A1 (zh) 2007-01-26
JP2003526632A (ja) 2003-09-09
PA8503201A1 (es) 2002-08-26
MXPA02003156A (es) 2002-09-30
BRPI0014382B8 (pt) 2021-05-25
PE20010607A1 (es) 2001-07-12
IL193367A0 (en) 2009-02-11
TW593315B (en) 2004-06-21
UA75053C2 (en) 2006-03-15
AR025752A1 (es) 2002-12-11
NO20021520L (no) 2002-05-23
WO2001023375A2 (fr) 2001-04-05
CN100374435C (zh) 2008-03-12
DE60041548D1 (de) 2009-03-26
BG65860B1 (bg) 2010-03-31
KR100895572B1 (ko) 2009-04-29
IL193368A (en) 2011-05-31
HK1091818A1 (zh) 2007-01-26
RS50369B (sr) 2009-11-10
PL366342A1 (en) 2005-01-24
AU782820B2 (en) 2005-09-01
HRP20020308B1 (fr) 2013-01-31
CN100422173C (zh) 2008-10-01
SK5912002A3 (en) 2003-01-09
ZA200202760B (en) 2003-10-29
WO2001023375A3 (fr) 2002-05-02
AU1569601A (en) 2001-04-30
CO5200835A1 (es) 2002-09-27
BG106637A (bg) 2003-02-28
EE05258B1 (et) 2010-02-15
ES2320525T3 (es) 2009-05-25

Similar Documents

Publication Publication Date Title
ZA200202760B (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity.
TR199902372A3 (tr) Sulfanilsilanlar.
TR200000520A3 (tr) 4-Fenil-piridin türevleri.
PT1164870E (pt) Barra de cereais
MA25391A1 (fr) Inhibiteurs d'alcenyl et alcynyl metalloproteases.
NL1016477A1 (nl) Gemodificeerd oxymethyleenpolymeer.
ES1041748Y (es) Pantalon perfeccionado.
ES1039434Y (es) Estanteria.
ES1043980Y (es) Juego de sube y baja perfeccionado.
ES1042318Y (es) Alfombrilla perfeccionada.
ES1042757Y (es) Barbacoa perfeccionada.
ES1037917Y (es) Juego perfeccionado.
ES1039867Y (es) Parrilla asadora perfeccionada.
ES1039262Y (es) Juego perfeccionado.
ES1041012Y (es) Juego componible perfeccionado.
ES1044268Y (es) Puzzle perfeccionado.
ES1044792Y (es) Colchon perfeccionado.
ES1044141Y (es) Juego didactico de ensamblaje de piezas tetraedricas regulares e irregulares.
ES1042789Y (es) Mueble perfeccionado.
ES1042333Y (es) Prenda perfeccionada.
ES1037420Y (es) Juego perfeccionado.
ES1038530Y (es) Juego perfeccionado.
IT245730Y1 (it) Perfezionato catetere transettale.
ES1040490Y (es) Mueble expositor-almacen.
ES1041565Y (es) Salva orejas y similares.